## S Claiborne Johnston

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11863296/publications.pdf

Version: 2024-02-01

204 papers

34,486 citations

14655 66 h-index 181 g-index

208 all docs

208 docs citations

times ranked

208

25767 citing authors

#	Article	IF	Citations
1	Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack. Stroke, 2014, 45, 2160-2236.	2.0	3,891
2	Forecasting the Future of Cardiovascular Disease in the United States. Circulation, 2011, 123, 933-944.	1.6	2,690
3	Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic Events. New England Journal of Medicine, 2006, 354, 1706-1717.	27.0	2,582
4	The ICH Score. Stroke, 2001, 32, 891-897.	2.0	1,851
5	Definition and Evaluation of Transient Ischemic Attack. Stroke, 2009, 40, 2276-2293.	2.0	1,543
6	Guidelines for Prevention of Stroke in Patients With Ischemic Stroke or Transient Ischemic Attack. Stroke, 2006, 37, 577-617.	2.0	1,510
7	Guidelines for the Prevention of Stroke in Patients With Stroke or Transient Ischemic Attack. Stroke, 2011, 42, 227-276.	2.0	1,433
8	Clopidogrel with Aspirin in Acute Minor Stroke or Transient Ischemic Attack. New England Journal of Medicine, 2013, 369, 11-19.	27.0	1,384
9	Validation and refinement of scores to predict very early stroke risk after transient ischaemic attack. Lancet, The, 2007, 369, 283-292.	13.7	1,160
10	Short-term Prognosis After Emergency Department Diagnosis of TIA. JAMA - Journal of the American Medical Association, 2000, 284, 2901.	7.4	1,132
11	Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA. New England Journal of Medicine, 2018, 379, 215-225.	27.0	844
12	Global variation in stroke burden and mortality: estimates from monitoring, surveillance, and modelling. Lancet Neurology, The, 2009, 8, 345-354.	10.2	823
13	Patients With Prior Myocardial Infarction, Stroke, or Symptomatic Peripheral Arterial Disease in the CHARISMA Trial. Journal of the American College of Cardiology, 2007, 49, 1982-1988.	2.8	752
14	Forecasting the Future of Stroke in the United States. Stroke, 2013, 44, 2361-2375.	2.0	636
15	Update to the AHA/ASA Recommendations for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack. Stroke, 2008, 39, 1647-1652.	2.0	450
16	Predictors of Rehemorrhage After Treatment of Ruptured Intracranial Aneurysms. Stroke, 2008, 39, 120-125.	2.0	433
17	Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack. New England Journal of Medicine, 2016, 375, 35-43.	27.0	424
18	Guidelines for Prevention of Stroke in Patients With Ischemic Stroke or Transient Ischemic Attack. Circulation, 2006, 113, .	1.6	416

#	Article	IF	Citations
19	Ticagrelor and Aspirin or Aspirin Alone in Acute Ischemic Stroke or TIA. New England Journal of Medicine, 2020, 383, 207-217.	27.0	333
20	Global Variation in the Relative Burden of Stroke and Ischemic Heart Disease. Circulation, 2011, 124, 314-323.	1.6	320
21	Hospital Usage of Early Do-Not-Resuscitate Orders and Outcome After Intracerebral Hemorrhage. Stroke, 2004, 35, 1130-1134.	2.0	302
22	Association Between <i>CYP2C19 &lt; /i&gt;Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack. JAMA - Journal of the American Medical Association, 2016, 316, 70.</i>	7.4	276
23	Cognitive Impairment and Decline Are Associated with Carotid Artery Disease in Patients without Clinically Evident Cerebrovascular Disease. Annals of Internal Medicine, 2004, 140, 237.	3.9	253
24	Longitudinal Risk of Intracranial Hemorrhage in Patients With Arteriovenous Malformation of the Brain Within a Defined Population. Stroke, 2004, 35, 1697-1702.	2.0	240
25	Endovascular and surgical treatment of unruptured cerebral aneurysms: Comparison of risks. Annals of Neurology, 2000, 48, 11-19.	5.3	238
26	Treatment of Unruptured Cerebral Aneurysms in California. Stroke, 2001, 32, 597-605.	2.0	227
27	The China National Stroke Registry for Patients with Acute Cerebrovascular Events: Design, Rationale, and Baseline Patient Characteristics. International Journal of Stroke, 2011, 6, 355-361.	5.9	227
28	Incomplete Inhibition of Thromboxane Biosynthesis by Acetylsalicylic Acid. Circulation, 2008, 118, 1705-1712.	1.6	210
29	Genetic Polymorphisms and Clopidogrel Efficacy for Acute Ischemic Stroke or Transient Ischemic Attack. Circulation, 2017, 135, 21-33.	1.6	200
30	National Stroke Association guidelines for the management of transient ischemic attacks. Annals of Neurology, 2006, 60, 301-313.	5.3	178
31	Clopidogrel With Aspirin in Acute Minor Stroke or Transient Ischemic Attack (CHANCE) Trial. Circulation, 2015, 132, 40-46.	1.6	178
32	Safety and efficacy of natalizumab in patients with acute ischaemic stroke (ACTION): a randomised, placebo-controlled, double-blind phase 2 trial. Lancet Neurology, The, 2017, 16, 217-226.	10.2	176
33	Efficacy and safety of ticagrelor versus aspirin in acute stroke or transient ischaemic attack of atherosclerotic origin: a subgroup analysis of SOCRATES, a randomised, double-blind, controlled trial. Lancet Neurology, The, 2017, 16, 301-310.	10.2	174
34	Effect of Endovascular Services and Hospital Volume on Cerebral Aneurysm Treatment Outcomes. Stroke, 2000, 31, 111-117.	2.0	171
35	Development and validation of outcome prediction models for aneurysmal subarachnoid haemorrhage: the SAHIT multinational cohort study. BMJ: British Medical Journal, 2018, 360, j5745.	2.3	166
36	The Transformational Effects of COVID-19 on Medical Education. JAMA - Journal of the American Medical Association, 2020, 324, 1033.	7.4	164

#	Article	IF	CITATIONS
37	Transient Ischemic Attack. New England Journal of Medicine, 2002, 347, 1687-1692.	27.0	163
38	Addition of Brain Infarction to the ABCD <sup>2</sup> Score (ABCD <sup>2</sup> I). Stroke, 2010, 41, 1907-1913.	2.0	158
39	Metrics for Measuring Quality of Care in Comprehensive Stroke Centers: Detailed Follow-Up to Brain Attack Coalition Comprehensive Stroke Center Recommendations. Stroke, 2011, 42, 849-877.	2.0	158
40	Dual antiplatelet therapy in stroke and ICAS. Neurology, 2015, 85, 1154-1162.	1.1	158
41	Recent advances in management of transient ischaemic attacks and minor ischaemic strokes. Lancet Neurology, The, 2006, 5, 323-331.	10.2	153
42	Outcomes Associated With Clopidogrel-Aspirin Use in Minor Stroke or Transient Ischemic Attack. JAMA Neurology, 2019, 76, 1466.	9.0	148
43	Ticagrelor versus Clopidogrel in <i>CYP2C19</i> Loss-of-Function Carriers with Stroke or TIA. New England Journal of Medicine, 2021, 385, 2520-2530.	27.0	147
44	Effect of a US National Institutes of Health programme of clinical trials on public health and costs. Lancet, The, 2006, 367, 1319-1327.	13.7	135
45	Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial: Rationale and design. International Journal of Stroke, 2013, 8, 479-483.	5.9	135
46	Statin Use During Ischemic Stroke Hospitalization Is Strongly Associated With Improved Poststroke Survival. Stroke, 2012, 43, 147-154.	2.0	134
47	The role of hypoventilation in a sheep model of epileptic sudden death. Annals of Neurology, 1995, 37, 531-537.	5.3	133
48	Head Computed Tomography Findings Predict Short-Term Stroke Risk After Transient Ischemic Attack. Stroke, 2003, 34, 2894-2898.	2.0	129
49	External Validation of the ICH Score. Neurocritical Care, 2004, 1, 53-60.	2.4	123
50	<i>C</i> linical- and <i>I</i> maging-Based <i>P</i> rediction of Stroke Risk After Transient Ischemic Attack. Stroke, 2009, 40, 181-186.	2.0	117
51	Central apnea and acute cardiac ischemia in a sheep model of epileptic sudden death. Annals of Neurology, 1997, 42, 588-594.	5.3	110
52	Higher ABCD <sup>2</sup> Score Predicts Patients Most Likely to Have True Transient Ischemic Attack. Stroke, 2008, 39, 3096-3098.	2.0	103
53	Intracranial atherosclerotic disease: An update. Annals of Neurology, 2009, 66, 730-738.	5.3	101
54	Application of the ABCD <sup>2</sup> Score to Identify Cerebrovascular Causes of Dizziness in the Emergency Department. Stroke, 2012, 43, 1484-1489.	2.0	99

#	Article	IF	CITATIONS
55	A comparison of risk factors for recurrent TIA and stroke in patients diagnosed with TIA. Neurology, 2003, 60, 280-285.	1.1	97
56	Safety and feasibility of a CT protocol for acute stroke: combined CT, CT angiography, and CT perfusion imaging in 53 consecutive patients. American Journal of Neuroradiology, 2003, 24, 688-90.	2.4	95
57	Cost-Effectiveness of Dabigatran Compared With Warfarin for Stroke Prevention in Patients With Atrial Fibrillation and Prior Stroke or Transient Ischemic Attack. Stroke, 2012, 43, 881-883.	2.0	92
58	Rationale and design of a randomized, double-blind trial comparing the effects of a 3-month clopidogrel-aspirin regimen versus aspirin alone for the treatment of high-risk patients with acute nondisabling cerebrovascular event. American Heart Journal, 2010, 160, 380-386.e1.	2.7	90
59	Ischemic Preconditioning From Transient Ischemic Attacks?. Stroke, 2004, 35, 2680-2682.	2.0	86
60	Ticagrelor plus aspirin versus clopidogrel plus aspirin for platelet reactivity in patients with minor stroke or transient ischaemic attack: open label, blinded endpoint, randomised controlled phase II trial. BMJ: British Medical Journal, 2019, 365, l2211.	2.3	86
61	Is hospitalization after TIA cost-effective on the basis of treatment with tPA?. Neurology, 2005, 65, 1799-1801.	1.1	84
62	Risk of Vascular Events in Emergency Department Patients Discharged Home With Diagnosis of Dizziness or Vertigo. Annals of Emergency Medicine, 2011, 57, 34-41.	0.6	82
63	Endovascular and surgical treatment of unruptured cerebral aneurysms: Comparison of risks. Annals of Neurology, 2000, 48, 11-19.	5.3	80
64	Thirty-Year Projections for Deaths From Ischemic Stroke in the United States. Stroke, 2003, 34, 2109-2112.	2.0	76
65	Effect of Clopidogrel plus ASA vs. ASA Early after TIA and Ischaemic Stroke: A Substudy of the CHARISMA Trial. International Journal of Stroke, 2011, 6, 3-9.	5.9	73
66	Effect of Statin Use During Hospitalization for Intracerebral Hemorrhage on Mortality and Discharge Disposition. JAMA Neurology, 2014, 71, 1364.	9.0	72
67	Dual Antiplatelet Therapy in Transient Ischemic Attack and Minor Stroke With Different Infarction Patterns. JAMA Neurology, 2018, 75, 711.	9.0	67
68	Ticagrelor Added to Aspirin in Acute Nonsevere Ischemic Stroke or Transient Ischemic Attack of Atherosclerotic Origin. Stroke, 2020, 51, 3504-3513.	2.0	67
69	Practice Variability in Management of Transient Ischemic Attacks. European Neurology, 1999, 42, 105-108.	1.4	65
70	Characteristics of Academic Medical Centers and Ischemic Stroke Outcomes. Stroke, 2001, 32, 2137-2142.	2.0	64
71	Are Patients With Acutely Recovered Cerebral Ischemia More Unstable?. Stroke, 2003, 34, 2446-2450.	2.0	63
72	Time Course for Benefit and Risk of Clopidogrel and Aspirin After Acute Transient Ischemic Attack and Minor Ischemic Stroke. Circulation, 2019, 140, 658-664.	1.6	63

#	Article	IF	CITATIONS
73	Early recovery after cerebral ischemia risk of subsequent neurological deterioration. Annals of Neurology, 2003, 54, 439-444.	5.3	62
74	Anticipating and Training the Physician of the Future: The Importance of Caring in an Age of Artificial Intelligence. Academic Medicine, 2018, 93, 1105-1106.	1.6	60
75	Temporal and Geographic Trends in the Global Stroke Epidemic. Stroke, 2013, 44, S123-5.	2.0	58
76	Natalizumab in acute ischemic stroke (ACTION II). Neurology, 2020, 95, e1091-e1104.	1.1	55
77	Modeling Treatment Effects on Binary Outcomes with Grouped-Treatment Variables and Individual Covariates. American Journal of Epidemiology, 2002, 156, 753-760.	3.4	52
78	Recurrent Stroke was Associated with Poor Quality of Life in Patients with Transient Ischemic Attack or Minor Stroke: Finding from the <scp>CHANCE</scp> Trial. CNS Neuroscience and Therapeutics, 2014, 20, 1029-1035.	3.9	50
79	A Cost–Utility Analysis of Mechanical Thrombectomy as an Adjunct to Intravenous Tissue-Type Plasminogen Activator for Acute Large-Vessel Ischemic Stroke. Stroke, 2011, 42, 2013-2018.	2.0	48
80	Estimated Association of Construction Work With Risks of COVID-19 Infection and Hospitalization in Texas. JAMA Network Open, 2020, 3, e2026373.	5.9	48
81	Risks and benefits of clopidogrel–aspirin in minor stroke or TIA. Neurology, 2017, 88, 1906-1911.	1.1	47
82	Neutrophil counts, neutrophil ratio, and new stroke in minor ischemic stroke or TIA. Neurology, 2018, 90, e1870-e1878.	1.1	47
83	Postictal Pulmonary Edema Requires Pulmonary Vascular Pressure Increases. Epilepsia, 1996, 37, 428-432.	5.1	46
84	Effect of clopidogrel with aspirin on functional outcome in TIA or minor stroke. Neurology, 2015, 85, 573-579.	1.1	44
85	Association of Lp-PLA <sub>2</sub> -A and early recurrence of vascular events after TIA and minor stroke. Neurology, 2015, 85, 1585-1591.	1.1	43
86	Statin Adherence Is Associated With Reduced Recurrent Stroke Risk in Patients With or Without Atrial Fibrillation. Stroke, 2017, 48, 1788-1794.	2.0	43
87	Stress Hyperglycemia and Prognosis of Minor Ischemic Stroke and Transient Ischemic Attack. Stroke, 2017, 48, 3006-3011.	2.0	43
88	National stroke association recommendations for systems of care for transient ischemic attack. Annals of Neurology, 2011, 69, 872-877.	5.3	42
89	Prevalence, knowledge, and treatment of transient ischemic attacks in China. Neurology, 2015, 84, 2354-2361.	1.1	41
90	Early Outcomes After Carotid Artery Stenting Compared With Endarterectomy for Asymptomatic Carotid Stenosis. Stroke, 2015, 46, 120-125.	2.0	41

#	Article	IF	Citations
91	Recurrent Stroke in Minor Ischemic Stroke or Transient Ischemic Attack With Metabolic Syndrome and/or Diabetes Mellitus. Journal of the American Heart Association, 2017, 6, .	3.7	40
92	Deaths from stroke in US young adults, 1989–2009. Neurology, 2014, 83, 2110-2115.	1.1	39
93	Gender Differences in Treatment of Severe Carotid Stenosis After Transient Ischemic Attack. Stroke, 2010, 41, 1891-1895.	2.0	38
94	Ischemic Transient Neurological Events Identified by Immune Response to Cerebral Ischemia. Stroke, 2012, 43, 1006-1012.	2.0	38
95	Risk for Major Hemorrhages in Patients Receiving Clopidogrel and Aspirin Compared With Aspirin Alone After Transient Ischemic Attack or Minor Ischemic Stroke. JAMA Neurology, 2019, 76, 774.	9.0	38
96	Intracranial Large Vessel Occlusion as a Predictor of Decline in Functional Status After Transient Ischemic Attack. Stroke, 2011, 42, 44-47.	2.0	36
97	Disability after minor stroke and TIA. Neurology, 2019, 93, e708-e716.	1.1	36
98	Disability After Minor Stroke and Transient Ischemic Attack in the POINT Trial. Stroke, 2020, 51, 792-799.	2.0	35
99	Electrocardiographic Findings Predict Short-term Cardiac Morbidity After Transient Ischemic Attack. Archives of Neurology, 2002, 59, 1437-41.	4.5	34
100	Chlamydia pneumoniae Burden in Carotid Arteries Is Associated With Upregulation of Plaque Interleukin-6 and Elevated C-Reactive Protein in Serum. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 2648-2653.	2.4	34
101	Endovascular Thrombectomy for Ischemic Stroke. JAMA - Journal of the American Medical Association, 2016, 316, 1265.	7.4	33
102	Association Between <i>ABCB1</i> Polymorphisms and Outcomes of Clopidogrel Treatment in Patients With Minor Stroke or Transient Ischemic Attack. JAMA Neurology, 2019, 76, 552.	9.0	33
103	Association of multiple infarctions and ICAS with outcomes of minor stroke and TIA. Neurology, 2017, 88, 1081-1088.	1.1	32
104	Real-time pandemic surveillance using hospital admissions and mobility data. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	7.1	31
105	Clinical outcomes according to permanent discontinuation of clopidogrel or placebo in the CHARISMA trial. Archives of Cardiovascular Diseases, 2009, 102, 485-496.	1.6	30
106	Patent Foramen Ovale Closure â€" Closing the Door Except for Trials. New England Journal of Medicine, 2012, 366, 1048-1050.	27.0	30
107	A global view of atherothrombosis: Baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. American Heart Journal, 2005, 150, 401.e1-401.e7.	2.7	29
108	Standardized discharge orders after stroke: Results of the quality improvement in stroke prevention (QUISP) cluster randomized trial. Annals of Neurology, 2010, 67, 579-589.	5.3	29

#	Article	IF	CITATIONS
109	Ticagrelor in Acute Stroke or Transient Ischemic Attack in Asian Patients. Stroke, 2017, 48, 167-173.	2.0	29
110	Antihypertensive Medications Prescribed at Discharge After an Acute Ischemic Cerebrovascular Event. Stroke, 2005, 36, 1944-1947.	2.0	28
111	Costâ€Effectiveness of Clopidogrelâ€Aspirin Versus Aspirin Alone for Acute Transient Ischemic Attack and Minor Stroke. Journal of the American Heart Association, 2014, 3, e000912.	3.7	28
112	Acute Stroke or Transient Ischemic Attack Treated with Aspirin or Ticagrelor and Patient Outcomes (Socrates) Trial: Rationale and Design. International Journal of Stroke, 2015, 10, 1304-1308.	5.9	28
113	Risk for Major Bleeding in Patients Receiving Ticagrelor Compared With Aspirin After Transient Ischemic Attack or Acute Ischemic Stroke in the SOCRATES Study (Acute Stroke or Transient Ischemic) Tj ETQq1	1 <b>0.</b> <i>6</i> 78431	.42 <b>§</b> BT /Ove
114	The Acute S <u>t</u> roke or Transient Isc <u>h</u> emic Attack Treated with Tic <u>a</u> gre <u>l</u> or and Aspirin for Pr <u>e</u> vention of <u>S</u> trial: Rationale and design. International Journal of Stroke, 2019, 14, 745-751.	5.9	28
115	Transient Ischemic Attacks. Stroke, 2006, 37, 320-322.	2.0	27
116	Elevated Neutrophil and Presence of Intracranial Artery Stenosis Increase the Risk of Recurrent Stroke. Stroke, 2018, 49, 2294-2300.	2.0	27
117	Design of COVID-19 staged alert systems to ensure healthcare capacity with minimal closures. Nature Communications, 2021, 12, 3767.	12.8	27
118	Efficacy of Clopidogrel for Prevention of Stroke Based on <i>CYP2C19</i> Allele Status in the POINT Trial. Stroke, 2020, 51, 2058-2065.	2.0	26
119	Validation of the Stroke Prognostic Instrument-II in a Large, Modern, Community-Based Cohort of Ischemic Stroke Survivors. Stroke, 2011, 42, 3392-3396.	2.0	25
120	Knowledge and management of transient ischemic attacks among US primary care physicians. Neurology, 2003, 61, 1455-1456.	1.1	24
121	Screen failure data in clinical trials: Are screening logs worth it?. Clinical Trials, 2014, 11, 467-472.	1.6	24
122	Time to Retire the Concept of <i>Transient Ischemic Attack</i> . JAMA - Journal of the American Medical Association, 2022, 327, 813.	7.4	23
123	Effect of Clopidogrel on the Rate and Functional Severity of Stroke Among High Vascular Risk Patients. Stroke, 2010, 41, 1679-1683.	2.0	22
124	Poststroke Neurological Improvement Within 7 Days Is Associated With Subsequent Deterioration. Stroke, 2004, 35, 2165-2170.	2.0	21
125	Acute dual antiplatelet therapy for minor ischaemic stroke or transient ischaemic attack. BMJ: British Medical Journal, 2019, 364, 1895.	2.3	21
126	Decision Making in Acute Stroke Care. Stroke, 2014, 45, 2144-2150.	2.0	20

#	Article	IF	CITATIONS
127	Treatment Effect of Clopidogrel Plus Aspirin Within 12ÂHours of Acute Minor Stroke or Transient Ischemic Attack. Journal of the American Heart Association, 2016, 5, e003038.	3.7	20
128	Efficacy and Safety of Ticagrelor in Relation to Aspirin Use Within the Week Before Randomization in the SOCRATES Trial. Stroke, 2018, 49, 1678-1685.	2.0	20
129	Editorial Commentâ€" Transient Ischemic Attacks Are Emergencies. Stroke, 2005, 36, 724-724.	2.0	19
130	Enhancing ties between academia and industry to improve health. Nature Medicine, 2011, 17, 434-436.	30.7	19
131	Improved Ischemic Stroke Outcome Prediction Using Model Estimation of Outcome Probability: The THRIVE-c Calculation. International Journal of Stroke, 2015, 10, 815-821.	5.9	19
132	Ticagrelor Versus Aspirin in Acute Embolic Stroke of Undetermined Source. Stroke, 2017, 48, 2480-2487.	2.0	19
133	Impact of CYP2C19 polymorphism in prognosis of minor stroke or TIA patients with declined eGFR on dual antiplatelet therapy: CHANCE substudy. Pharmacogenomics Journal, 2018, 18, 713-720.	2.0	19
134	Association of Black Race With Early Recurrence After Minor Ischemic Stroke or Transient Ischemic Attack. JAMA Neurology, 2020, 77, 601.	9.0	19
135	Carotid Stenosis and Recurrent Ischemic Stroke. Stroke, 2021, 52, 2414-2417.	2.0	19
136	A Simple Risk Index and Thrombolytic Treatment Response in Acute Ischemic Stroke. JAMA Neurology, 2014, 71, 848.	9.0	18
137	Academic Medical Centers. JAMA - Journal of the American Medical Association, 2019, 322, 203.	7.4	18
138	Transient ischemic attack: A neurologic emergency. Current Neurology and Neuroscience Reports, 2005, 5, 13-20.	4.2	17
139	Effect of Clopidogrel by Smoking Status on Secondary Stroke Prevention. Circulation, 2017, 135, 315-316.	1.6	17
140	Ticagrelor Added to Aspirin in Acute Ischemic Stroke or Transient Ischemic Attack in Prevention of Disabling Stroke. JAMA Neurology, 2021, 78, 177.	9.0	17
141	Intracranial Hemorrhage During Dual Antiplatelet Therapy. Journal of the American College of Cardiology, 2021, 78, 1372-1384.	2.8	17
142	Cilostazol for Secondary Stroke Prevention. Stroke, 2021, 52, e635-e645.	2.0	17
143	Short-term prognosis after a TIA: a simple score predicts risk Cleveland Clinic Journal of Medicine, 2007, 74, 729-736.	1.3	17
144	Evaluation and management of transient ischemic attack: an important component of stroke prevention. Nature Clinical Practice Cardiovascular Medicine, 2007, 4, 310-318.	3.3	16

#	Article	IF	Citations
145	Cerebral small vessel disease or intracranial large vessel atherosclerosis may carry different risk for future strokes. Stroke and Vascular Neurology, 2020, 5, 128-137.	3.3	16
146	Clopidogrel with Aspirin in Minor Stroke or Transient Ischemic Attack. New England Journal of Medicine, 2013, 369, 1375-1377.	27.0	15
147	Effect of Estimated Glomerular Filtration Rate Decline on the Efficacy and Safety of Clopidogrel With Aspirin in Minor Stroke or Transient Ischemic Attack. Stroke, 2016, 47, 2791-2796.	2.0	15
148	The Economic Case for New Stroke Thrombolytics. Stroke, 2010, 41, S59-62.	2.0	14
149	Prognostication matters. , 2000, 23, 839-842.		13
150	Diffusion-weighted MRI in evaluation of transient ischemic attack. Journal of Stroke and Cerebrovascular Diseases, 2003, 12, 137-142.	1.6	13
151	Early editorial manuscript screening versus obligate peer review: A randomized trial. Annals of Neurology, 2007, 61, A10-A12.	5.3	13
152	Factors Associated With the Decision to Hospitalize Patients After Transient Ischemic Attack Before Publication of Prediction Rules. Stroke, 2008, 39, 411-413.	2.0	13
153	Trends in Usage of Alternative Antiplatelet Therapy After Stroke and Transient Ischemic Attack. Stroke, 2008, 39, 1228-1232.	2.0	13
154	High-sensitivity C-reactive protein and clopidogrel treatment in patients at high risk of cardiovascular events: a substudy from the CHARISMA trial. Heart, 2011, 97, 626-631.	2.9	13
155	Outcome Assessment by Central Adjudicators Versus Site Investigators in Stroke Trials. Stroke, 2019, 50, 2187-2196.	2.0	13
156	Effects of the September 11th attacks on urgent and emergent medical evaluations in a Northern California managed care plan. American Journal of Medicine, 2002, 113, 556-562.	1.5	12
157	Assessment of the End Point Adjudication Process on the Results of the Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial. JAMA Network Open, 2019, 2, e1910769.	5.9	12
158	Efficacy of Clopidogrel-Aspirin Therapy for Stroke Does Not Exist in <i>C</i> YP2C19 Loss-of-Function Allele Noncarriers With Overweight/Obesity. Stroke, 2020, 51, 224-231.	2.0	12
159	Methodologies for pragmatic and efficient assessment of benefits and harms: Application to the SOCRATES trial. Clinical Trials, 2020, 17, 617-626.	1.6	12
160	Transient Ischemic Attack: A Dangerous Harbinger and an Opportunity to Intervene. Seminars in Neurology, 2005, 25, 362-370.	1.4	11
161	Race-ethnicity on blood pressure control after ischemic stroke: a prospective cohort study. Journal of the American Society of Hypertension, 2017, 11, 38-44.	2.3	11
162	Comparative Effectiveness of Aspirin and Clopidogrel Versus Aspirin in Acute Minor Stroke or Transient Ischemic Attack. Stroke, 2019, 50, 101-109.	2.0	11

#	Article	IF	CITATIONS
163	Efficacy and Safety of Ticagrelor and Aspirin in Patients With Moderate Ischemic Stroke. JAMA Neurology, 2021, 78, 1091.	9.0	11
164	Oxidized low-density lipoprotein predicts recurrent stroke in patients with minor stroke or TIA. Neurology, 2018, 91, e947-e955.	1.1	10
165	Restart TICrH: An Adaptive Randomized Trial of Time Intervals to Restart Direct Oral Anticoagulants after Traumatic Intracranial Hemorrhage. Journal of Neurotrauma, 2021, 38, 1791-1798.	3.4	10
166	Ischemic Benefit and Hemorrhage Risk of Ticagrelor-Aspirin Versus Aspirin in Patients With Acute Ischemic Stroke or Transient Ischemic Attack. Stroke, 2021, 52, 3482-3489.	2.0	9
167	Urgent neurology consultation from the ED for transient ischemic attack. American Journal of Emergency Medicine, 2011, 29, 601-608.	1.6	8
168	Impact of Increased Early Statin Administration on Ischemic Stroke Outcomes: A Multicenter Electronic Medical Record Intervention. Journal of the American Heart Association, 2016, 5, .	3.7	8
169	Transient Neurological Attack. JAMA - Journal of the American Medical Association, 2007, 298, 2912.	7.4	7
170	Prevention of Stroke Following Transient Ischemic Attack. Current Atherosclerosis Reports, 2011, 13, 330-337.	4.8	7
171	Applying principles from the game theory to acute stroke care: Learning from the prisoner's dilemma, stag-hunt, and other strategies. International Journal of Stroke, 2016, 11, 274-286.	5.9	7
172	Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack. New England Journal of Medicine, 2016, 375, 1394-1395.	27.0	7
173	Evaluation of Systolic Blood Pressure, Use of Aspirin and Clopidogrel, and Stroke Recurrence in the Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke Trial. JAMA Network Open, 2021, 4, e2112551.	5.9	7
174	P2Y12 Inhibitors Plus Aspirin Versus Aspirin Alone in Patients With Minor Stroke or High-Risk Transient Ischemic Attack. Stroke, 2021, 52, 2250-2257.	2.0	7
175	Infarct on Brain Imaging, Subsequent Ischemic Stroke, and Clopidogrel-Aspirin Efficacy. JAMA Neurology, 2022, 79, 244.	9.0	7
176	Time Course for Benefit and Risk of Ticagrelor and Aspirin in Acute Ischemic Stroke or Transient Ischemic Attack. Neurology, 2022, 99, .	1.1	7
177	Time Course for Benefit and Risk With Ticagrelor and Aspirin in Individuals With Acute Ischemic Stroke or Transient Ischemic Attack Who Carry <i>CYP2C19</i> Loss-of-Function Alleles. JAMA Neurology, 2022, 79, 739.	9.0	7
178	The 2008 William M. Feinberg Lecture. Stroke, 2008, 39, 3431-3436.	2.0	6
179	Estimated treatment effect of ticagrelor versus aspirin by investigator-assessed events compared with judgement by an independent event adjudication committee in the SOCRATES trial. International Journal of Stroke, 2019, 14, 908-914.	5.9	6
180	Hyperglycemia, Risk of Subsequent Stroke, and Efficacy of Dual Antiplatelet Therapy: A Post Hoc Analysis of the POINT Trial. Journal of the American Heart Association, 2022, 11, e023223.	3.7	6

#	Article	IF	CITATIONS
181	Antiplatelet Use and Ischemic Stroke Risk in Minor Stroke or Transient Ischemic Attack: A Post Hoc Analysis of the POINT Trial. Stroke, 2021, 52, e773-e776.	2.0	5
182	A Cross-Sectional Study of Individuals Seeking Information on Transient Ischemic Attack and Stroke Symptoms Online: A Target for Intervention?. PLoS ONE, 2012, 7, e47997.	2.5	4
183	Voluntary Site Accreditation — Improving the Execution of Multicenter Clinical Trials. New England Journal of Medicine, 2017, 377, 1414-1415.	27.0	4
184	Leaving Tiny, Unruptured Intracranial Aneurysms Untreated. JAMA Neurology, 2018, 75, 13.	9.0	4
185	Lp-PLA2 and dual antiplatelet agents in intracranial arterial stenosis. Neurology, 2020, 94, e181-e189.	1.1	4
186	Bleeding Risk of Dual Antiplatelet Therapy after Minor Stroke or Transient Ischemic Attack. Annals of Neurology, 2022, 91, 380-388.	5.3	4
187	Towards FASTER treatment of TIA and minor stroke. Lancet Neurology, The, 2007, 6, 941-943.	10.2	3
188	Stroke prediction after TIA: avoiding an alphabet soup. Lancet Neurology, The, 2010, 9, 1039-1040.	10.2	3
189	The US Training System for Physiciansâ€"Need for Deeper Analysis. JAMA - Journal of the American Medical Association, 2018, 320, 982.	7.4	3
190	Time to Loading Dose and Risk of Recurrent Events in the SOCRATES Trial. Stroke, 2019, 50, 675-682.	2.0	3
191	F2R Polymorphisms and Clopidogrel Efficacy and Safety in Patients With Minor Stroke or TIA. Neurology, 2021, 96, e1-e9.	1.1	3
192	Newly Diagnosed Atrial Fibrillation After Transient Ischemic Attack Versus Minor Ischemic Stroke in the POINT Trial. Journal of the American Heart Association, 2021, 10, e019362.	3.7	3
193	Aligning academic medicine within the healthcare system: the APS-SPR virtual chat series. Pediatric Research, 2023, 93, 503-510.	2.3	2
194	Indobufen versus aspirin in acute ischaemic stroke (INSURE): rationale and design of a multicentre randomised trial. Stroke and Vascular Neurology, 2022, 7, e001480.	3.3	2
195	Letter by Elkins et al Regarding Article, "Blocking of α4 Integrin Does Not Protect From Acute Ischemic Stroke in Mice― Stroke, 2014, 45, e195.	2.0	1
196	The Risk and Cost of Limited Clinician and Patient Accountability in Health Care. JAMA - Journal of the American Medical Association, 2019, 322, 1759.	7.4	1
197	Effect of Hypertension on Efficacy and Safety of Ticagrelor-Aspirin Versus Clopidogrel-Aspirin in Minor Stroke or Transient Ischemic Attack. Stroke, 0, , .	2.0	1
198	The Concept of Transient Ischemic Attack—Reply. JAMA - Journal of the American Medical Association, 2022, 327, 2457.	7.4	1

#	Article	IF	CITATIONS
199	Chapter 23 Identification, risks, and treatment of transient ischemic attack. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2008, 93, 453-473.	1.8	0
200	Response to Letter by O'Kelly and Macdonald. Stroke, 2008, 39, .	2.0	0
201	Stroke mortality in the Seychelles: methodological issues – Authors' reply. Lancet Neurology, The, 2009, 8, 700.	10.2	0
202	Response by Wang and Johnston to Letter Regarding Article, "Ticagrelor in Acute Stroke or Transient Ischemic Attack in Asian Patients: From the SOCRATES Trial (Acute Stroke or Transient Ischemic Attack) Tj ETQq0	O2OorgBT/	Overlock 10
203	Medical Education in Need of a 2020 Revamp. NEJM Catalyst, 2020, 1, .	0.7	O
204	No rebound effect after a course of clopidogrel in patients with acute TIA or minor stroke. Neurological Research, $0$ , , $1$ -7.	1.3	0